
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA is a Germany-based company in the Healthcare sector with a market capitalisation of $14.7B. Its FinScore is 52/100; its highest-scoring layer is Value (82) and its lowest is Growth (25). The shares trade at 8.6x trailing earnings and are down 2% year to date.
Share price performance
About Fresenius SE & Co. KGaA
www.fresenius.comFresenius SE & Co. KGaA operates as a prominent global healthcare entity, delivering an array of products and services primarily centered around dialysis, hospital operations, and outpatient medical care. Its extensive operations are strategically structured into four distinct segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division concentrates on comprehensive solutions for individuals suffering from chronic kidney disease, providing crucial products like dialyzers and advanced hemodialysis machines, alongside related disposable items and essential dialysis services. The Fresenius Kabi segment focuses on the critical care and long-term therapy of acutely and chronically ill patients. Its extensive portfolio encompasses intravenously administered generic drugs for various therapeutic areas such as oncology, pain management, anesthesia, anti-infectives, and intensive care. It also supplies parenteral and enteral nutrition products, infusion solutions, blood volume expanders for infusion therapy, and advanced biosimilars targeting autoimmune and oncological conditions. Furthermore, this segment manufactures the necessary medical devices for drug and nutritional therapy administration, as well as specialized transfusion products for blood component collection and therapeutic apheresis. Fresenius Helios manages an expansive network of healthcare facilities, including 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers across Germany, complemented by 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers in Spain. Beyond general care, this segment also specializes in fertility treatments, operating 33 clinics and 39 additional sites spread across 10 countries on three continents. Finally, Fresenius Vamed provides project management and specialized services for the development and operation of hospitals and other healthcare infrastructure. Its offerings range from initial project conception and detailed planning to turnkey construction, in addition to ongoing maintenance, technical oversight, and full operational management services. Established in 1912, the company initially traded as Fresenius SE before adopting its current designation, Fresenius SE & Co. KGaA, in January 2011. Its corporate headquarters are situated in Bad Homburg vor der Höhe, Germany.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- HQ
- Germany
- Fiscal year-end
- December
- Trading currency
- CHF
- Reporting currency
- EUR
- Fundamentals updated
- 6 days ago
- Market cap
- $14.7B
- Shares outstanding
- 296.1M
- P/E (TTM)
- 8.6x
- Dividend yield (TTM)
- 4.26%
- Beta (issuer)
- 0.83
- Revenue (latest FY)
- €22.9B
Revenue breakdown
Revenue split not available
FinScore
As of 2026-10-19Snapshot
Ownership
Holder data is not available for this company yet.
Sign up or log in to see Analysis
Analysis for Fresenius SE & Co. KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Fresenius SE & Co. KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Fresenius SE & Co. KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Fresenius SE & Co. KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Fresenius SE & Co. KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Fresenius SE & Co. KGaA is available to Finryse members. The Overview stays open to everyone; creating an account is free.